Clinical Trial

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)

Recruiting
View on ClinicalTrials.gov →
Summary
30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous system (ANS) dysfunction in the chronic kidney disease (CKD) stage 3-5 setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-08.
Status change: Not Yet Recruiting → Recruiting 2025-12-29
Trial Details
NCT Number NCT06927024
Lead Sponsor NYU Langone Health
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Chronic Kidney Diseases
Enrollment 30 participants
Start Date 2025-10-15
Primary Completion 2029-01-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-31